Tesamorelin + Ipamorelin Blend: Pre-Cycle vs Post-Cycle Research

Real Peptides does not publish pre-cycle or post-cycle guidance for a tesamorelin + ipamorelin blend, and a wholesale buyer should be wary of any supplier that does. "Pre-cycle" and "post-cycle" describe a human administration sequence, which sits entirely outside research-use-only framing. The comparison that actually belongs on a buyer's desk is a sourcing comparison: whether a pre-blended vial or two separately tested single-compound vials gives you cleaner documentation, simpler inventory, and a purity record you can stand behind. This article covers how the two compounds differ in the published literature, how the blend-versus-separate decision plays out operationally, and what to verify before you place an order with anyone.

Why cycle framing doesn't carry over to a research catalog

The pre-cycle and post-cycle vocabulary comes from performance and bodybuilding communities, where it describes when a person takes something relative to something else. Research peptides are not sold on those terms. They are laboratory materials, not FDA-approved drugs, and they are not for human consumption — which means sequencing, timing, and protocol questions have no answer a compliant supplier can give you.

That has a practical read-through for buyers. When a supplier is willing to publish administration charts, cycle lengths, or stacking schedules, it tells you something about how that company understands its own regulatory position. It does not tell you anything about whether the material in the vial is what the label says it is. The two things are easy to confuse, because protocol content looks like expertise and a certificate of analysis looks like paperwork. For a business putting its own name behind a catalog, the paperwork is the expertise.

Your downstream obligations — what your business may lawfully do with research compounds, how they must be labeled, who may purchase them from you — belong to your attorney and, where applicable, your state board. What a supplier owes you is narrower and more checkable: identity, purity, batch traceability, consistent supply, and pricing you can see before you commit.

Where tesamorelin and ipamorelin differ in published research

Both compounds appear in literature on the growth hormone axis, but they are studied at different receptors, which is the reason they come up together in combination discussions at all.

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone. Published research characterizes it as acting at the GHRH receptor on pituitary somatotrophs, with structural modification intended to improve stability relative to native GHRH in study conditions. Ipamorelin is a pentapeptide growth hormone secretagogue; studies report activity at the ghrelin receptor (GHS-R1a) and describe it as comparatively selective against earlier-generation secretagogues in the models tested. Research interest in pairing a GHRH analogue with a secretagogue follows from exactly that split — two distinct receptor pathways within the same endocrine system.

None of that is a claim about outcomes in people, and it should not be presented to your own customers as one.

The last row is the one most buyers skip. Two compounds in the same research category do not share a certificate of analysis, and a supplier that produces one document covering a product line rather than a batch has given you a brochure.

Blended vial or two single-compound vials?

This is the decision a wholesale buyer can actually make, and it comes down to verification and flexibility rather than science.

For most catalogs, separate single-compound vials are the stronger operational choice. They are easier to verify, easier to document, easier to shelve, and easier to drop or scale independently as demand shifts. Blends mostly exist because they simplify a seller's story, not because they simplify a buyer's books.

There is also a labeling dimension. A single-compound vial with a batch-matched certificate is a straightforward thing to describe accurately in your own product listings. A proprietary mixture is harder to describe without drifting into claims about what the combination does — and that drift is where compliance problems usually begin.

What to verify before you order either compound from anyone

Treat this as a standing checklist, not a one-time diligence exercise. Suppliers change manufacturers, and documentation quality tends to move with them.

Batch-matched certificates of analysis. The COA should reference the specific lot number printed on the vial you receive, not a representative sample from an earlier run. Ask whether you can view it without logging in, emailing a rep, or paying for it. Charging for test results, or releasing them only on request, is a pattern worth noticing.

A stated purity method and figure. HPLC purity should be reported as a number tied to that lot. Identity confirmation by mass spectrometry answers a different question — whether the peptide is the right sequence at all — and a serious supplier reports both rather than treating purity alone as sufficient.

Testing breadth beyond purity. Purity tells you how much of the vial is the intended compound. It does not tell you what the remainder is. Panel testing that extends past a single chromatogram is the difference between a number and a picture.

Pricing you can see. Tier structure, minimum order quantities, and the terms for moving between tiers should be visible before you apply, not disclosed after a sales call. Hidden pricing is not a negotiation tactic; it is a sign that the number depends on how much the seller thinks you'll pay.

Fulfillment you can plan around. Where orders ship from, how long fulfillment takes, and what happens to a lot that fails testing are all answerable questions. Vague answers here become your stockouts later.

Research-use-only labeling. Vials and documentation should be labeled for laboratory research use. A supplier whose packaging implies anything else has created a problem you will inherit.

Licensing, labeling, and the questions to take to counsel

This section is informational and is not legal advice. The regulatory picture for reselling research compounds is not uniform, and it is not something a supplier can resolve on your behalf.

The durable approach is to arrive at your attorney's office with the right questions rather than expecting a general answer. Among them: how your business entity and any professional licenses it holds interact with the sale or transfer of research-use-only materials; what your state board, if one governs your category, expects regarding materials that are not FDA-approved drugs; how your labeling, website copy, and sales materials must be worded to stay consistent with research-use-only status; what recordkeeping you are expected to maintain on sourcing and batch documentation; and whether anything about your customer base changes the analysis.

In most states, these questions have answers that depend on specifics a general article cannot know. Check with your state board and your own counsel before building a catalog around any assumption. What you can control in the meantime is documentation quality — a supplier that gives you verifiable, batch-level records makes every one of those conversations shorter.

What Real Peptides does differently

Real Peptides builds the wholesale relationship around verification rather than persuasion. Compounds are tested to 99%+ HPLC purity, and each batch runs through 7-panel testing rather than a purity figure alone. Certificates of analysis are publicly verifiable — a prospective partner can check lab results directly, before applying, without a sales conversation and without paying for the document. Testing is not an upsell and it is not an on-request favor.

Fulfillment is handled domestically, with orders shipping in 5–7 days, so inventory planning runs on a known window rather than an open-ended import timeline. Wholesale pricing is tiered and disclosed to approved partners rather than quoted case by case.

The Wholesale Partner Program application is a 3-step process. It exists to confirm that a partner is a legitimate business buying research-use-only materials, not to create a gate that produces a phone call. All compounds are sold for laboratory research use only, and Real Peptides does not provide dosing, preparation, or sequencing guidance for any of them — including for compounds that are frequently discussed together in the literature.

If your business is ready to stock these compounds

If you operate a med spa, clinic, telehealth company, or reseller brand and you are building a growth-factor research category, the practical next move is to pull the published certificates for the specific compounds you care about, compare them against whatever your current supplier provides, and submit the Wholesale Partner Program application once the documentation holds up. That order — verify first, apply second — is the one that tends to produce a supplier relationship you don't have to revisit.

Buyers researching this category usually look at Tesamorelin 10mg and Ipamorelin 10mg as separate line items, often alongside CJC-1295 No DAC 10mg when they are comparing GHRH-analogue research materials; the wider growth factor and tissue signaling research collection and the popular peptides catalog show where each of these sits relative to the rest of the line.